

Fysisk träning under preoperativ cellgiftsbehandling för bröstcancer för att öka andelen patienter som får komplett tumörrespons: den randomiserade Neo-ACT studien

2023-01017-02 Ansökan om ändring Ändringsansökan, Med biologiskt material Avvakta avgift - inkommen ansökan

Jana de Boniface

1.1.1. Ange diarienummer och beslutsdatum på den tidigare godkända grundansökan.

2022-06669-02

2022-12-14

1.1.1.1. Ange vilken nämnd/myndighet som behandlade grundansökan

Etikprövningsmyndigheten (beslut fr.o.m. 2019)

1.1.2.1 Ska projektets titel bytas?

Nej

1.1.3. Ange diarienummer och beslutsdatum för eventuella tidigare ändringsansökningar och ge en kort summering av vad de avsåg. Om antalet tidigare ändringar överstiger fem ska en separat förteckning över ändringsansökningarna biläggas.

2022-04236-02, 2022-09-12: Ändringen avser tillägg av flera forskningshuvudmän, förtydligande av dataflödet i forskningspersonsinformationen och mindre ändringar i studieprotokollet. 2022-05694-02, 2022-11-09: Ändringen avser godkännande av nya protokollversionen 1.2 och forskningspersonsinformationen 2.1, i samråd med biobanksansvarig Stockholms Medicinska Biobank (SMB)

2022-06669-02, 2022-12-14: Tillägg av KI biobank som ansvarig biobank.

1.2.1 Ange ansvarig forskare för den tidigare godkända grundansökan.

Jana de Boniface, jana.de-boniface@ki.se

1.2.3. Ange forskningshuvudman för den tidigare godkända grundansökan.

Karolinska Institutet (202100-2973)



1.2.3.1 Behörig företrädare för grundansökans forskningshuvudman

Anders Franco Cereceda

1.2.3.2 Behörig företrädare grundansökan – titel som innebär ett verksamhetsansvar

Professor, prefekt

1.3. Beskriv kortfattat den ändring av tidigare godkänd ansökan som planeras.

Ändringen avser reviderad protokollversion 1.3 daterat 2023-02-10.

1.3.1. Sammanfattning av ändring

Reviderat protokoll förtydligar detaljer på interventionen, inklusionskriteriet "fullständig tumörbiologi", rapportering av adverse events och insamlad baseline-data samt öppnar för remote monitoring.

1.4. Ange de skäl som ligger till grund för den planerade ändringen.

Uppdatering av detaljer efter start av studien och återkoppling från sites.

1.5. Gör en värdering av hur förhållandet mellan riskerna och nyttan av projektet förändras med anledning av den planerade ändringen.

Förändras ej genom denna ändring.

1.6. Kommer informationen till forskningspersonerna förändras med anledning av den planerade ändringen.

Nej

1.7 Söker projektet förtur med motivering att projektet har tydlig potential att ge nytta i närtid för behandling och förebyggande av COVID-19?

Nej

1.7. Kommer annan information/bilagor förändras med anledning av den planerade ändringen.

Ja

1.7.1. Beskriv hur annan information/bilagor förändras med anledning av den planerade ändringen.

Protokoll 1.3: Förtydligande av interventionen

Etikprövningsmyndigheten



Öppning för remote monitoring Borttagande av PR, Ki67 och grad som inklusionskriterier(ej krav för bestämning av subtyp) Förtydligande av ITT populationen Förtydligande om rapportering av AE och SAE

1.8. Ange i förekommande fall vilka bilagor som bifogas ansökan.

Trial protocol version 1.3 20230210_EPN

Bifoga relevanta bilagor

relevanta_bilagor-Trial_protocol_Neo_ACT_1.3_20230210_EPN.pdf 623.15KB

1.9 Huvudansvarig forskare för projektet (kontaktperson):

Jana de Boniface

Ange behörig företrädare för befintlig forskningshuvudman

Anders Franco Cereceda

Är behörig företrädare för befintlig huvudman ordinarie eller tillförordnad?

Ordinarie företrädare

Signaturer

Signatur-huvudansvariga-forskare.pdf 29.71KB

Signatur-behoriga-foretradare.pdf 31.02KB

Beslut och handlingar från Etikprövningsmyndigheten

Beslutsbrev och andra handlingar från Etikprövningsmyndigheten i relation till denna ansökan

2023-01017-02_Avgiftsavisering.pdf 34.54KB



Physical exercise during neoadjuvant chemotherapy for breast cancer as a means to increase pathological complete response rates: the randomized Neo-ACT trial

NCT05184582 (www.clinicaltrials.gov)

Full trial protocol version 1.3

Dated February 10, 2023

VERSION IDENTIFIER

Version 1.0, April 3, 2022

Version 1.1, July 10, 2022

Version 1.2, November 9, 2022

Version 1.3, February 10, 2023

Any relevant amendments to the protocol are first submitted to the responsible ethical committee and after approval disseminated to all participating sites. Changes that are not deemed relevant in accordance to guidance from the ethical committee, such as minor errors or discrepancies between the latest approved informed consent form and the protocol are released without ethical amendment and designated with a third number in the protocol version.

SPONSOR

Karolinska Institutet, Dept. of Molecular Medicine and Surgery, 17176 Stockholm

PRINCIPAL INVESTIGATORS

Jana de Boniface (overall coordinating investigator), Associate Professor, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, and Department of Surgery, Capio St. Göran's Hospital, Stockholm Sweden.

Yvonne Wengström (coordinating investigator exercise), Professor, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

Renske Altena (coordinating investigator oncology/toxicity/translational research), PhD, Medical Unit Breast, Endocrine Tumours and Sarcoma, Theme Cancer, Karolinska University Hospital, Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden

Cecilia Haddad Ringborg (coordinator exercise), PhD, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

INTERNATIONAL COLLABORATION

Peeter Karihtala (national coordinator Finland), Professor, Research Director at Helsinki University Hospital, Comprehensive Cancer Center, Finland

ADVISOR PATHOLOGY

Johan Hartman, Professor, Karolinska Institutet, Dept. of Oncology-Pathology

ADVISOR RADIOLOGY

Sophia Zackrisson, Professor, Skåne University Hospital Malmö and Lund University

COLLABORATORS TRANSLATIONAL PROJECTS

Johan Hartman, Professor, Karolinska Institutet, Dept. of Oncology-Pathology

Theodoros Foukakis, Associate Professor., Karolinska Institutet, Dept. of Oncology-Pathology

Dhifaf Sarhan, Associate Professor, Karolinska Institutet, Dept of Laboratory Medicine

Barbro Linderholm, Associate Professor, Sahlgrenska University Hospital, Dept. of Oncology

TRIAL STATISTICIAN

Robert Szulkin, PhD, Scandinavian Development Services, Danderyd, Sweden

PATIENT REPRESENTATIVE

Åsa Magnusson, Swedish Breast Cancer Association (Bröstcancerförbundet)

TRIAL COORDINATING CENTER

Clinical Trial Office (CTO) Centre for Clinical Cancer Studies (CKC) Theme Cancer Karolinska University Hospital 17176 Stockholm

Project manager: Natalia Pohl, <u>natalia.pohl@regionstockholm.se</u> Monitor, Sweden: Yvonne Larsén, <u>yvonne.larsen@regionstockholm.se</u> DATA MANAGEMENT

Mats Hellström, data manager, Clinical Trials Office, Karolinska University Hospital, Stockholm, Sweden

TABLE OF CONTENTS

Version identifier	2
Sponsor	2
Principal investigators	2
International collaboration	2
Advisor Pathology	3
Advisor Radiology	3
Collaborators translational projects	3
Trial statistician	3
Patient representative	3
Trial Coordinating Center	3
Data management	
Synopsis	7
Background	11
Purpose and aims	13
Hypotheses	14
Method	15
Study design	15
Population	15
Intervention	16
Control	
Outcomes, Variables and measures	19
Study calendar	21
Data management	22
Monitoring and follow-up	22
End of trial	23
Adverse Events	23
Estimated sample size and power	25
Statistical analysis plan	25
Ethical considerations	
Withdrawal	
Publication policy	
Time plan	

Translational research	32
Faeces microbiome	32
Intratumoral and circulating Natural Killer (NK) cells	33
Tumour gene profiling	34
Tumour microenvironment	34
Circulating tumour cells and tumour DNA	35
The effects of human adipocytes on breast cancer progression and metastasis	35
Deep proteomics of inflammatory regulators in cancer	
References	

Title	Physical exercise during neoadjuvant chemotherapy for breast cancer
	as a means to increase pathological complete response rates
Short title	Neo-ACT trial (NCT05184582)
Trial design	Prospective randomized clinical trial
Trial rationale	Neoadjuvant chemotherapy (NACT) is the current standard of care for patients with breast tumours larger than 20 mm and/or lymph node metastases, particularly Human Epidermal growth factor Receptor 2 (HER2) and triple negative breast cancer (TNBC). The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of residual invasive tumour in the breast and the axillary lymph nodes. Today, pCR is frequently used as surrogate endpoint in oncological pharmaceutical trials focusing on new compounds often in combination with the current standard of care. While NACT has the advantage to offer fast-track approval of new drug compounds in oncology, early expectations of improved survival rates have not been
	met. Additional systemic drug regimens come, however, at a cost, and associated side effects and toxicities are important to bear in mind. It is therefore utterly compelling to conceive that improved NACT efficacy – and thus de-escalated locoregional therapy – may be achieved by a non-toxic patient-driven life-style intervention such as physical exercise.
	Being physically active reduces the risk for breast cancer by 20-30%, and exercise induces reductions of tumour growth in animal models of breast cancer. Exercise may act through reduced systemic inflammation and enhanced anti-tumoural immune cell function, improve blood flow and perfusion and thus tumour susceptibility to systemic treatment, reduce systemic inflammation and enhance immune cell functions. The short-term stress of a single bout of physical exercise in healthy human subjects can induce a release of immune cells into the circulation, and primary tumour growth is reduced in mice exposed to voluntary running.
	Physical exercise during chemotherapy is feasible and safe. Observational studies show that exercise in breast cancer has a protective effect regarding recurrence and mortality. Long-term follow-up of aerobic and resistance exercise shows enhanced survival

SYNOPSIS

	in patients with breast cancer. In the randomized OptiTrain trial, resistance and high-intensity interval training (HIIT) during postoperative chemotherapy had positive effects on fatigue and muscle strength, muscle mass and function. Chemotherapy completion rates are improved by exercise. Exercise may thus result in improved	
	pCR rates through systemic anti-inflammatory effects and improved	
	chemotherapy completion rates given at full dosage due to the favourable effects of exercise on treatment tolerability.	
Endpoints	The primary endpoint is pathological complete response (pCR).	
Linupolitio	The secondary endpoints are:	
	- Residual Cancer Burden (RCB)	
	- Objective radiological tumour response (RECIST)	
	- All-cause, breast cancer-specific, and recurrence-free survival at 2, 5	
	and 10 years	
	- Health-related quality of life assessed by the EORTC QLQ-C30 and	
	BR23 questionnaires - Self-reported physical activity (Modified Godin Leisure Time	
	Physical activity questionnaire)	
	- Toxicity-related outcomes (chemotherapy completion rates, number	
	of unplanned hospital admissions during NACT, objective cognitive	
	dysfunction (Amsterdam Cognition Scan), cardiac toxicity and sick	
	leave) Device measured physical activity level (Fithit activity tracker)	
	 Device-measured physical activity level (Fitbit activity tracker) Muscle strength (handgrip strength test and hypothetical 1-RM maximal leg muscle strength tests) 	
	- Cardiorespiratory fitness (Ekblom-Bak submaximal cycle test)	
Patient	Clinically T1-3, N0-2 breast cancer patients scheduled for NACT and	
selection	surgery with curative intent.	
	Inclusion criteria:	
	Patients with primary invasive breast cancer cT1-T3 cN0-2	
	 Tumour subtype (ER, PRHER2) available before initiation of 	
	NACT	
	Oral and written consent	
	• Age \geq 18 years	
	Exclusion criteria	
	Bilateral invasive breast cancer	
	Pregnancy or breast-feeding	

	• The presence of musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may prevent safe completion of the exercise and testing demands of the trial	
	 Currently performing equal to or more than 150 mins of 	
	moderate to high intensity aerobic exercise plus 2 sessions per	
	week of moderate intensity resistance exercise	
Intervention	Participants randomized to the exercise group will complete two	
	home-based 60-min exercise sessions per week from initiation of	
	NACT to surgery (approx. five months):	
	• Progressive home exercise program by an individualised mobile	
	phone application, supported by local physiotherapists. and by	
	<mark>online meetings</mark>	
	• Initial exercise intensity individually tailored to each patient's	
	fitness at baseline and rate of perceived exertion during the	
	program and adapted if required.	
	 Sessions will begin with a 3-minute moderate intensity (12-13 on 	
	Borg's Rate of Perceived Exertion (RPE) scale) warm-up.	
	bolg s hate of referived Exercition (in E) search warm up.	
	Before initiation of the training sessions, the participants register	
	personal information about their current physical health together with	
	the physiotherapist to individually design the training program. The	
	participants will perform Tabata type exercises that the mobile phone	
	application generates automatically based on updated information	
	provided by the participants before each training session.	
	In addition to the exercise intervention, patients will be encouraged to	
	accumulate further 150 minutes of physical activity each week.	
	No exercise within 48 hours of chemotherapy administration.	
Control	Routine information on benefit of physical exercise as per clinical	
F -ll	guidelines and local practice.	
Follow-up	Each patient is followed up for two years after surgery regarding	
	secondary endpoints. Survival and recurrence data are obtained via	
Statistical	national registers at 5 and 10 years. Patients will be randomized in a 1:1 fashion. In order to detect an	
considerations	increase of the pCR rate in the experimental arm by 10%, which is	
	regarded clinically relevant, and using a power of 80% and an alpha	
	of 5%, a total of 712 patients have to be included; 356 in each arm.	
	Accounting for a drop-out of 10%, the trial will include 790 patients.	
	Stratification at the moment of computerized randomization will be	
	berachiered on at the moment of compaterized randomization will be	

	based on hospital and biological tumour subtype (ER+HER2-, ER+HER2+, ER-HER2+, ER-HER2-).
Time plan	Trial initiation: October 2022
	Enrolment phase: October 2022 – December 2025
	Reporting of primary endpoint: September 2026

BACKGROUND

Use of neoadjuvant (preoperative) chemotherapy in breast cancer

Neoadjuvant chemotherapy (NACT) has a history of being reserved for non-operable, locally advanced breast cancer (BC) but is increasingly used for patients with early BC. It is strongly recommended by national¹ and international² guidelines especially in the triple-negative (TNBC) and HER2-positive BC subtypes, and in case of lymph node metastases. In Sweden, 14% of all newly diagnosed early BC patients suitable for surgery (1041 out of 7289 individuals according to the National Breast Cancer Register) received NACT in 2019 (22% in Stockholm), while this figure was 35% (Stockholm 45%) for TNBC and HER2-positive BC, and 50% (Stockholm 62%) for all clinically node-positive BC. Combining lymph node metastases and tumour subtype, the rate of NACT was as high as 68% (Stockholm 80%) in clinically node-positive TNBC and HER2-positive BC in 2019.

The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of residual invasive tumour in the breast and the axillary lymph nodes. Especially in the abovementioned tumour subtypes TNBC and HER2-positive breast cancer, published pCR rates are high (50.7% in TNBC and 63.7% in HER2-positive, oestrogen receptor (ER)-negative BC) and strongly predict improved survival³. In luminal BC (ER-positive, HER2-negative), published pCR rates are substantially lower (10.8% if HER2 negative, 29.4% if HER2 positive)³ which underlines the need for novel regimens including anti-endocrine strategies. Today, pCR is frequently used as surrogate endpoint in oncological pharmaceutical trials focusing on new compounds often in combination with the current standard of care (traditionally chemotherapy and/or targeted therapies with anti-HER2 and anti-ER drugs, but now also immunotherapy, CDK4/6 inhibitors and drug-antibody conjugates).

Need to improve pCR rates

While NACT has the advantage to offer fast-track approval of new drug compounds in oncology, such as the FDA approval of pertuzumab after the Neosphere trial published first in 2012⁴, early expectations of improved survival rates simply by reversing the traditional order of treatments (surgery followed by adjuvant systemic therapy) have not been met⁵. Only recently, however, the Keynote 522 trial could show both a higher pCR rate and an improved event-free survival in TNBC patients receiving the anti-PD1 antibody pembrolizumab, which fuels hopes that specific subgroups will be identified who gain a survival benefit from NACT when compared to standard treatment⁶. Apart from improving outcomes in specific subgroups, NACT facilitates research into post-neoadjuvant systemic treatment strategies, which has already resulted in supplemental therapies such as adjuvant capecitabine in HER2-negative BC⁷ and T-DM1 in HER2-positive BC⁸. It also allows for less extensive surgery by tumour shrinkage and conversion of node-positive BC into node-

negative disease, which may be of great benefit for the individual patient in terms of postoperative morbidity and quality of life. Additional systemic drug regimens come, however, at a cost, and associated side effects and toxicities are important to bear in mind. It is therefore utterly compelling to conceive that improved NACT efficacy – and thus de-escalated locoregional therapy – may be achieved by a non-toxic patient-driven life-style intervention such as physical exercise. Such patient empowerment is especially important in the view of the common clinical observation that most patients request to know how they themselves may contribute to a favourable course of their disease and treatment.

Evidence on physical exercise and cancer

Epidemiological research shows that being physically active reduces the risk for breast cancer by 20-30%⁹ and has a similarly protective effect in women carrying high-risk BC mutations such as BRCA1 and BRCA2¹⁰. Since the 1960s, numerous intervention studies report exercise-induced reductions of tumour growth in animal models of breast cancer¹¹. Mechanistically oriented preclinical trials suggest that exercise act through reduced systemic inflammation and enhanced anti-tumoural immune cell function^{12,13}. Other studies show an altered phenotype of tumour vasculature with exercise, improving blood flow and perfusion, making the tumour more susceptible to systemic treatment^{12,13}. Further suggested mechanisms for the anti-tumoural effects of exercise include weight control, endocrine effects, less systemic inflammation (reflected by lower CRP and pro-inflammatory cytokine levels in serum), improved immune cell functions such as increased recruitment and cytotoxic activity of CD8+ T-cells and NK cells, and a shift towards an anti-tumorigenic (Th1/M1) profile¹²⁻¹⁴. In the tumour microenvironment, the level of inflammatory cell infiltration increases markedly in response to physical exercise¹⁵. Here, immune cells can provide anti-tumour immune responses and thus improve survival outcomes, or instead facilitate tumour growth and metastasis. Infiltrating cytotoxic CD8+ T-cells and NK cells predict a favourable clinical outcome in several solid human cancers, including breast cancer; in contrast, high levels of infiltrating T-regulatory cells and myeloid cells are linked to tumour progression and poor prognosis¹⁵. The short-term stress of a single bout of physical exercise in healthy human subjects can induce a release of immune cells such as granulocytes, monocytes and NK cells, as well as CD4- and CD8-positive T-cells¹⁶ into the circulation. In a recent study, primary tumour growth was reduced in multiple murine tumour models exposed to voluntary running¹⁷. This was attributed to enhanced tumour infiltration of NK cells, activated by an increase in systemic levels of epinephrine during exercise¹⁸. Very recently, a non-randomised prospective trial evaluated physical exercise during neoadjuvant treatment in patients with oesophageal cancer; participants in the exercise group had significantly more tumour regression at surgery than those in the control group¹⁹.

Physical exercise and chemotherapy

Physical exercise during chemotherapy is deemed feasible and safe²⁰, even when performed via tailored home-based exercise during neoadjuvant chemotherapy²¹. We have evidence from observational studies showing that exercise following a BC diagnosis has a protective effect regarding recurrence, all-cause and cancer-specific mortality²². Furthermore, long-term follow-up of a randomized exercise intervention consisting of aerobic and resistance exercise showed enhanced recurrence-free and overall survival in patients with breast cancer^{23,24}. In the randomized OptiTrain trial, resistance and high-intensity interval training (HIIT) during postoperative chemotherapy had positive effects on fatigue and muscle strength²⁵, muscle mass and function²⁶.

Chemotherapy completion at full dosage is strongly associated with an improved prognosis²⁷, but dose reductions occur in at least a third of BC patients. Importantly, chemotherapy completion rates can be improved by an exercise program of combined resistance and aerobic training²⁸. Physical exercise may thus result in improved pCR rates after NACT not only through proposed systemic anti-inflammatory effects, but also through improved chemotherapy completion rates given at full dosage due to the favourable effects of exercise on fatigue, muscle strength and cardiorespiratory fitness which drive improvements in treatment tolerability. Thus, there is great potential for physical exercise to be put forward as a feasible and effective strategy to support patients to tolerate treatments, which needs to be corroborated in prospective trials.

Physical exercise during NACT and its effects on treatment response and on pCR rates has never been tested. According to clinicaltrials.gov (searched March 22, 2022), there are only two open randomized physical exercise trials in neoadjuvant treatment of BC with oncological outcomes, namely the BENEFIT trial (Germany, N=120) and the Neo-Train trial (Denmark, N=100). Both small trials have the reduction of tumour size through NACT as their primary endpoint. Another trial is registered but not yet recruiting, the NEOLIFE trial (no oncological endpoint, NCT04135586). The Neo-ACT trial goes one step further and explores physical exercise as a means to improve oncological outcomes on a clinically relevant scale.

PURPOSE AND AIMS

The Neo-ACT trial is a prospective randomized controlled multicentre trial testing the effect of a physical exercise intervention during neoadjuvant chemotherapy (NACT) on the primary endpoint pathological complete response (pCR). Secondary aims are responserelated outcomes (RCB, RECIST), patient-related outcomes (health-related quality of life, self-reported physical activity), physiological outcomes (muscle strength, cardiorespiratory fitness, device-measured physical activity), and toxicity-related outcomes (cognitive dysfunction, chemotherapy completion rates, unplanned hospital admissions, cardiac toxicity, sick leave). Furthermore, the trial will explore how physical exercise affects anti-tumoral mechanisms inherent to therapy or host by hypothesis-generating translational analyses in a patient subset.

HYPOTHESES

1. A physical exercise intervention improves pCR rates by 10% in the intervention group as compared with the control group.


2. A physical exercise intervention improves secondary outcomes such as response-related outcomes (RCB, RECIST), patient-related outcomes (health-related quality of life, self-reported physical activity), physiological outcomes (muscle strength, cardiorespiratory fitness, device-measured physical activity), and toxicity-related outcomes (cognitive dysfunction, chemotherapy completion rates, unplanned hospital admissions, cardiac toxicity, sick leave).

Translational hypotheses will be tested in a subpopulation and will address which biological factors and mechanisms, assessed by contemporary translational studies from blood, faeces and tissue samples, are involved in anti-tumoral effects induced by physical exercise.

METHOD

STUDY DESIGN

The Neo-ACT trial is a prospective randomized trial with the primary endpoint pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) for breast cancer (BC).



POPULATION

Clinically T1-3, N0-2 BC patients scheduled for NACT and surgery with curative intent and fulfilling all inclusion criteria and no exclusion criteria as listed below. Patients with oligometastases scheduled for treatment with curative intent are eligible. Baseline stratification is performed based on treating hospital and biological tumour subtype (ER+HER2-, ER+HER2+, ER-HER2+, ER-HER2-) prior to randomization.

Eligible patients are identified at pre-NACT multidisciplinary team conferences and then receive information about the trial by their oncologist or surgeon, avoiding undue delays. Informed consent is mandatory before randomization and can be obtained by physician or nurse with the appropriate delegation. All participants will undergo standardised tests of physical condition and strength before start of NACT and after NACT but before surgery.

Inclusion criteria	Exclusion criteria
Patients with primary invasive	Bilateral invasive breast cancer
breast cancer cT1-T3 cN0-2	Pregnancy or breast-feeding
• Tumour subtype available before	• The presence of musculoskeletal,
initiation of NACT (<mark>ER, PR, HER2,</mark> tumour	neurological, respiratory, metabolic or
<mark>grade, and Ki67</mark>)	cardiovascular conditions that may prevent
Written informed consent	safe completion of the exercise and testing
• Age ≥ 18 years	demands of the study
	• Currently performing equal to or
	more than 150 mins of moderate to high
	intensity aerobic exercise plus 2 sessions
	per week of moderate intensity resistance
	exercise (WHO criteria)

In case of pre-term abortion of NACT, participants may remain on the trial. Participants who have not received at least four treatment cycles (three weekly treatments of e.g. paclitaxel correspond to one treatment cycle) as NACT are excluded from per-protocol analyses (see statistical analysis plan).

INTERVENTION

Participants randomized to the exercise group will complete two 60-min home-based exercise sessions per week from initiation of NACT to surgery (approx. five months) via a mobile application. To digitalise exercise interventions:

- Patients will receive instructions by an exercise physiologist or physiotherapist and perform training via the individualised training mobile application Vitala, supported by contact with a local physiotherapist/physiologist and remotely via zoom.
- The Vitala mobile phone application provides exercise instructions and support and measures program adherence and symptom reporting. Videos of variations of the resistance training are included in the app and are individually adapted to each participant.
- Initial exercise intensity will be individually tailored to each patient's fitness at baseline and rate of perceived exertion during the program and adapted if required
- Sessions will begin with a 3-minute moderate intensity (12-13 on Borg's Rate of Perceived Exertion (RPE) scale) warm-up.
- The aim of the exercise program is for participants to reach an perceived exertion level of 14-16 RPE on the Borg Scale.

• In case a patient does not feel capable of performing 60 min of exercise in one single session, sessions may be split into several occasions of at least 20 min per session, to amount to a total of 120 min of training sessions per week.

AEROBIC EXERCISE COMPONENT

The application will provide the participants with aerobic interval training exercises that will be performed at home. Some examples of exercises are running on the spot, jumping jacks etc. It will also be possible for the participants to perform aerobic exercise outdoors, e.g., running or bicycling. During the aerobic exercise component, participants should reach 16-18 RPE on the Borg's Scale.

RESISTANCE EXERCISE COMPONENT

Moderate intensity progressive resistance exercises will include different exercises. Some examples are chest and leg press, seated row, bicep curl, triceps press, leg curl, and abdominal exercises performed as home-based exercises. In addition, patients will be encouraged to accumulate further 150 minutes of physical activity each week.

COMPLIANCE: SUPERVISED VERSUS HOME-BASED EXERCISE

In analogy to drug compliance, it is important for patients to adhere to the exercise prescription. Consequently, research has focused on strategies to enhance both attendance and adherence to exercise interventions. Technological support in the form of mobile apps is a potential sustainable strategy to improve attendance and adherence to exercise and rehabilitation programs²⁹. On the other hand, the effects of exercise on health are increased if the exercise program at least initially includes supervision³⁰. Health care systems unfortunately rarely have the resources to invite every patient undergoing NACT to supervised weekly exercises. To increase feasibility and reach out to as many patients as possible, distance-based approaches must therefore be included. Another advantage of home-based exercise is that it significantly reduces time and travel burden for patients who often have frequent appointments. Thus, it is vital that the proposed trial investigates innovative and potentially sustainable strategies to implement exercise programs for patients with cancer.

THE MOBILE APPLICATION

Participants randomised to the intervention group will receive instructions to download and use the training Vitala mobile application. Vitala has been developed to support patients with various physical limitations and diseases in need of medical exercise programs, in both rural and urban areas, and help them to independently create and maintain exercise routines.

The main features of the Vitala app include a Medical Exercise Generator specifically adapted to this trial and in-app self-monitoring services. Before using the app, participants receive instructions and guidance on how to set up and use the app, and fill out an in-app health questionnaire to ensure that all of Vitala's functionalities and features are custom-tailored for each user.

The Vitala app has been developed in co-creation with patients and a cross-disciplinary research team consisting of researchers in physiotherapy, medicine, informatics and computer science, including experts in e-health. The app provides a large repository of evidence-based exercises in video formats and allows the user (in this case the trial team) to independently create an individualized medical exercise program based on preferences, disease, perceived energy levels and functional limitations. To help the patient to adhere to the program, the app offers feedback on exercise pattern, access to self-monitoring and possibility to submit questions regarding the program.



CONTROL

The aim of the trial is to compare the effects of an exercise program with routine care rather than to test a specific type of exercise. Thus, the control group is a routine care control group, which commonly implies brief verbal, general information about the benefits of physical activity from the treating physicians or breast cancer nurses. Participation in voluntary training groups organised by the treating hospital is not encouraged for participants since this implies that physical activity is potentially increased to the level specified in exclusion criteria. It is important to acknowledge that individuals consenting to an exercise trial may be more predisposed to exercising and may thus continue performing physical exercise if they are allocated to the control group. To measure this potential effect, all physical activity of both groups will be digitally collected so any "contamination" in the control group can be accounted for in the analysis. Importantly, the trial pursues an active recruitment strategy in order to meet potential participants at their respective fitness level however little they may be used to exercise. The control group will not have access to trial-specific exercises via the mobile application during the duration of the trial.

OUTCOMES, VARIABLES AND MEASURES

The **primary endpoint** pCR is measured by histopathological assessment according to the TNM classification of the American Joint Committee on Cancer (ypT0/is ypN0) after breast and axillary surgery (approx. 5 months after initiation of NACT, according to standard of care).

In order to ensure congruence in assessment of pCR between study sites, a central review of histopathological tumour slides will be performed for all included cases. Routine slides will be collected from participating sites on completion of the trial and digitally scanned for central pathology review at Karolinska University Hospital in Stockholm. Slides will thereafter be returned to the study sites.

The **secondary** endpoints are:

- 1. Residual Cancer Burden (RCB), calculated using primary tumour bed area (mm x mm), overall cancer cellularity (%), percentage of cancer that is in situ disease (%), number of positive lymph nodes and diameter of largest nodal metastasis (<u>http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3</u>). Categories are RCB-0 (pCR), RCB-I, RCB-II and RC-III.
- 2. Objective radiological tumour response according to RECIST v1.1 criteria³¹, measured as % change from largest radiological diameter of target lesion at baseline to pre-surgery (mammography or magnetic resonance tomography). No more than two target lesions are measured, which are the largest measurable lesions within the breast. Categories are: complete response (CR, disappearance of all target lesions), partial response (PR, at least a 30% decrease in the sum of the largest diameter (LD) of target lesions, taking as reference the baseline sum LD), progressive disease (PD, at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions) and stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started).
- 3. Overall, breast cancer-specific and recurrence-free survival at 2, 5 and 10 years. For overall survival, censuring is at death or at date for latest follow-up. For breast cancer-specific survival, censuring is at breast cancer-specific death or at date of last follow-up. For recurrence-free survival, censuring is at first local, regional or distant recurrence or at death or date of last follow-up. Contralateral invasive or in situ breast cancer or non-breast secondary malignancies are not counted as an event, in accordance with STEEP criteria³².

- 4. Health-related quality of life including fatigue, assessed by the EORTC QLQ-C30 and BR23 questionnaires (baseline, pre-surgery, 1- and 2-year follow-up)
- 5. Self-reported physical activity (Modified Godin Leisure Time Physical activity questionnaire) at baseline, pre-surgery, and 1- and 2-year follow-up, facilitating subsequent adjustment for any cross-contamination in the control group.
- 6. Toxicity-related outcomes:
 - a. Chemotherapy completion rates, i.e. the proportion of participants receiving the planned number of treatments at full dosage regarding neoadjuvant chemotherapy (measured pre-surgery).
 - b. Number of unplanned hospital admissions during neoadjuvant chemotherapy.
 - c. Objective cognitive dysfunction measured by an online neuropsychological test (Amsterdam Cognition Scan)³³ (baseline and 1-year follow-up).
 - d. Cardiac toxicity (defined as either left ventricular ejection fraction (LVEF) decline >15% or LVEF decline below an absolute value of 50% or clinical heart failure), to be measured by echocardiogram at baseline and after 3 months of NACT in the HER2-positive subgroup
 - e. Sick leave (patient-reported percentage of sick leave as a single measurement pre-surgery and at 1- and 2-year follow-up)
- 7. Device-measured physical activity level and resting heart rate assessed through the Fitbit activity tracker (baseline to 1-year follow-up).
- 8. Muscle strength assessed through the handgrip strength test and hypothetical 1-RM maximal leg muscle strength tests (baseline and pre-surgery).
- 9. Cardiorespiratory fitness assessed by the Ekblom-Bak submaximal cycle test (baseline and pre-surgery).

ADDITIONAL MEASURES

Attendance to the exercise sessions and adherence to the exercise prescription will be continually monitored and recorded. Sense of coherence measured by the SOC-13 scale and the Swedish version of the original Self-Efficacy for Exercise (SEE) scale will be used to better understand who adheres to and attends the exercise intervention.

Participant demographics, disease and medical history, body mass index, age, sex, education level, and smoking status will be recorded. Since this trial is not powered to assess survival and recurrence rates, follow-up will end two years after surgery. Register data will however be used in order to investigate overall and BC-specific survival rates after 2, 5 and 10 years.

Time point		
Baseline (before initiation of	 Verify eligibility 	
NACT)	Informed consent	
	Three 14G tumour biopsie	s in addition to diagnostic
	biopsy*	
		plasma, serum, whole blood) *
	Faeces samples *	
	• Full tumour biology (ER, PR, HER2, tumour grade, and	
	Ki67)	
	Baseline questionnaires and testi	0
	1. EORTC QLQ-C30 (quality of life)	
	2. EORTC QLQ-B23 (quality of life, breast cancer)	
	 Sense of coherence (SOC-13) Godin Leisure Time Self-Reported Physical Activity 	
	 Godin Leisure Time Self-F questionnaire 	reported i hysical Activity
	5. Self-Efficacy of Exercise (SEE) questionnaire
	6. Hand grip muscle strengt	
	7. 1-RM leg press test	
	8. Ekblom-Bak submaximal	cardiorespiratory cycle test
	9. Amsterdam Cognition Sca	
	10. <mark>Height/weight (BMI), boc</mark>	ly fat composition, blood
	pressure, patient and disease characteristics	
Randomization	Standard: Usual care	
	Intervention: Physical exercise	
Pre-surgery	Repeat baseline questionnaires a	
	Device-measured physical activit	
	Blood (45 ml for plasma and seru	m) and faeces samples *.
	Descriptions of the second sectors and the second s	
	-	and treatment details (CRF)
Surgery	Breast and axillary surgery: endp	and treatment details (CRF) oint pCR assessed and recorded.
	Breast and axillary surgery: endp Tumour tissue collected and stor	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank*
Postoperative treatment	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine
Postoperative treatment Follow-up (years after	Breast and axillary surgery: endp Tumour tissue collected and stor	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank*
Postoperative treatment Follow-up (years after surgery)	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival Godin (physical activity)	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival Godin (physical activity) SEE scale	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x x x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival Godin (physical activity) SEE scale Amsterdam Cognition Scan	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x x x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x x x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival Godin (physical activity) SEE scale Amsterdam Cognition Scan Device-measured physical	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x x x x x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x x x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival Godin (physical activity) SEE scale Amsterdam Cognition Scan Device-measured physical activity (Fitbit activity	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x x x x x x x x x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x x x
Postoperative treatment Follow-up (years after surgery) EORTC QLQ-C30 EORTC QLQ-B23 Record recurrence and survival Godin (physical activity) SEE scale Amsterdam Cognition Scan Device-measured physical	Breast and axillary surgery: endp Tumour tissue collected and stor Adjuvant treatment as per clinica 1 x x x x x x x x x x x	and treatment details (CRF) oint pCR assessed and recorded. ed at trial biobank* l routine 2 x x x x x

STUDY CALENDAR

* Stockholm sites only

DATA MANAGEMENT

Data are registered using an electronic Case Report Form (eCRF) and supplementary documentation at physical testing (source data). Monitoring is performed according to Good Clinical Practice (GCP) guidelines. The eCRF provides data on patient and disease characteristics deriving from medical history, clinical, radiological and histopathological assessment, details concerning type, dose and duration of neoadjuvant and adjuvant systemic therapy, as well as histopathological results at surgery and data on follow-up. Data are managed by the Clinical Trial Office at Centre for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden. Security is comparable to bank security with encrypted data.

Recorded information is pseudonymised and the key kept at each responsible site. Keys may however need to be transferred to trial staff for quality assurance purposes such as central review of pathology slides and central review of imaging. Information is confidential and the database is privacy-protected, i.e., no data can be traced back to the patient in research reports and no unauthorized individuals may have access to the data about individuals in the database. The database will be maintained until further notice (at least 20 years after inclusion of the last patient) and be reported in accordance with General Data Protection Regulation (GDPR). The authority responsible for the database is Karolinska Institutet, Stockholm, Sweden.

The Neo-ACT trial is registered at www.clinicaltrials.gov (NCT05184582).

MONITORING AND FOLLOW-UP

This prospective trial is conducted according to GCP guidelines and monitored by the Clinical Trial Office at Centre for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden, for Swedish sites, and further CROs in further countries participating in this trial. CROs will be monitoring inclusion and exclusion criteria as well as completeness and accuracy of data recorded in the eCRF by regular on-site and/or remote visits. To this end, participating units will grant access to patient medical records in due time on request. Patients are informed about monitoring procedures and medical record access in the patient information leaflet and grant their consent to these by signing the consent form.

Each patient is followed for two years after surgery regarding secondary endpoints. Followup can be conducted as telephone call or by post, and includes access to the participant's medical record in order to check for survival and recurrence. Follow-up must be performed within +/- two months from the surgery date, and data are to be completed in the eCRF within one month from the follow-up date. Long-term follow-up regarding survival and recurrence is conducted via national registers. Participating sites that do not adhere to GCP guidelines or to the agreements stated in the agreements signed between the medically responsible and local investigator at the individual site and Karolinska Institutet may be excluded from this trial.

END OF TRIAL

The trial will end for each participant followed for two years after the date of surgery, but also for participants who die, withdraw consent or are lost to follow-up.

ADVERSE EVENTS

An Adverse Event (AE) is any untoward medical occurrence in a patient or a clinical investigation subject which does not necessarily have a causal relationship with the trial intervention. An AE can therefore be any unfavourable or unintended finding, symptom, or disease temporally associated with a trial intervention, whether or not related to it.

The local investigator will only document AEs of specific interest in relation to the intervention or any exercise that participants in the control groups perform without relation to the trial. **No AEs related to NACT should be reported.** Exercise-related AEs to be reported are e.g.:

- New exercise-related pain or muscle soreness (requiring a modification or interruption of the exercise intervention or causing the participant to be prescribed pain killers by a physician)
- Long-term fatigue (the participant experiences extreme fatigue for more than 14 days).

Changes in the exercise program due to recent oncological treatment or due to presence of metastases are *not* reported as AE. The local investigator assesses and records the AEs observed during the AE reporting period, which is from the date of patient consent signature until the date of surgery.

A Serious Adverse Event (SAE) (ClinO, Art. 63) is any untoward medical occurrence that results in death or is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or causes a congenital anomaly or birth defect. Local investigators make a causality assessment of the event to the trial intervention or any exercise performed unrelated to the trial in the control group (see table below). Any event assessed as possibly, probably or definitely related is classified as related to the trial intervention. **Only SAEs related to physical exercise, be it**

as trial intervention or as leisure activity, but not SAEs related to NACT should be documented.

Causality of AEs to trial intervention is assessed according to the following scale:

Not related	The AE is clearly not related to the trial intervention. It is independent of
	trial intervention, or evidence prevails that it is related to other aetiology.
Unlikely	The AE is doubtfully related to the trial intervention. Temporal association
	between the AE and the trial intervention and the nature of the AE is such
	that the trial intervention is not likely to have had any reasonable
	association with the observed AE (cause and effect relationship
	improbable but not impossible).
Possibly	The AE may be related to the trial intervention. Less clear temporal
	association; other aetiologies also possible.
Probably	The AE is likely related to the trial intervention. Clear-cut temporal
	association; a potential alternative aetiology is not apparent.
Definitely	The AE is clearly related to the trial intervention. Clear-cut temporal
	association, and no other possible cause.

Severity assessment: Local investigators make a severity assessment of the event according to the Common Terminology Criteria for Adverse Events Version 5 published November 27, 2017³⁴.

Grade 1	Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only;
	intervention not indicated.
Grade 2	Moderate; minimal, local or non-invasive intervention indicated; limiting age-
	appropriate instrumental ADL.
Grade 3	Severe or medically significant but not immediately life-threatening;
	hospitalization or prolongation of hospitalization indicated; disabling; limiting
	self-care ADL.
Grade 4	Life-threatening consequences; urgent intervention indicated.
Grade 5	Death related to AE.

A Semi-colon indicates 'or' within the description of the grade. ADL: activities of daily living AEs have to be reported as SAE only when they are related (possibly, probably, definitely) to trial intervention. Trial intervention-related or other exercise-related SAEs in the control group are documented and reported immediately (within a maximum of 24 hours) to the Principal Investigators.

All AEs will be followed until they have abated, or until a stable situation has been reached. Depending on the event, follow-up may require additional tests or medical procedures as indicated, and/or referral to a general physician or a medical specialist.

ESTIMATED SAMPLE SIZE AND POWER

Patients will be randomized in a 1:1 fashion. It is anticipated that the rate of the primary endpoint pCR will be approximately 30% in the control arm. We aim to increase the rate of pCR in the experimental arm to 40%, i.e. a 10 percentage points increase, which is regarded clinically relevant since it would translate into improved disease-related outcomes. With a power of 80% and an alpha of 5%, a total of 712 patients have to be included; 356 in each arm. Accounting for a drop-out of 10%, we aim to include 790 patients. Stratification at the moment of computerized randomization will be done based on site of treatment (hospital) and biological tumour subtype (ER+HER2-, ER+HER2+, ER-HER2+, ER-HER2-).

STATISTICAL ANALYSIS PLAN

All outcomes will primarily be analysed using an intention-to-treat approach, i.e. all study subjects will belong to the treatment group (exercise intervention or control) they were assigned to, disregarding compliance. Participants who choose to withdraw consent between randomization and the date of first NACT will however not be regarded as part of the ITT population and their data will not be reported in any analysis. As sensitivity analysis, all outcomes will also be analysed using a per-protocol approach, meaning that participants in the intervention group who comply with less than 65% of the prescribed physical exercise program or complete less than 40% of the planned neoadjuvant systemic therapy (around two 3-weekly courses) will be excluded from analysis.

Covariate adjustment in statistical models

Guidelines from the European Medicines Agency (EMA) regarding statistics and covariate adjustments recommend that factors that are used to stratify the randomization, i.e. site of treatment and biological tumour type in this trial, should be accounted for in the statistical analysis^{35,36}. However, it is also recognized that "limited numbers of subjects per centre will make it impracticable to include the centre effects in the statistical model". In this trial it is very likely that some of the centres will contribute few patients, which may cause problems in some of the statistical models, in particular for the categorical outcomes (such as the primary endpoint, pCR) where the variability in the outcome may be too small within each site. Hence, the statistical models, described below, will primarily be adjusted for biological tumour type and not for study site. If appropriate and if the data allows (i.e. no convergence problems and not too small subgroups), the site effect will also be incorporated in the models

as a random effect in the mixed models and as a fixed factor in the remaining logistic regression models.

PRIMARY ENDPOINT (PCR)

The primary outcome in this trial (pCR) is dichotomous, and will be assessed through histopathological examination of the surgical specimen after completed NACT. Hence, a multivariable logistic regression model, adjusting for biological tumour type (stratification factor in the randomization) will be used. The treatment effect will be assessed in terms of the resulting odds ratio between the two treatment arms together with a 95% confidence interval and a complementary Wald test. A two-sided statistical test with 5% significance level will be used. Furthermore, differences in pCR rates between the two treatment arms will be explored for each biological tumour type subgroup (ER+HER2-, ER+HER2+, ER-HER2+, ER-HER2+, ER-HER2-), using an interaction between treatment and biological tumour type.

SECONDARY ENDPOINTS

1. Residual Cancer Burden (RCB)

Residual Cancer Burden (RCB) is measured as four ordered categories (RCB-0 which corresponds to pCR, RCB-I, RCB-II, and RC-III) at histopathological assessment of the surgical specimen. An ordinal regression model, adjusting for biological tumour type (stratification factor in the randomization), will be used to analyse differences between the treatment arms. If the proportional odds assumption of the model is violated, a nominal regression model or a generalized logistic model will be used instead if appropriate.

2. Objective radiological tumour response

Response Evaluation Criteria in Solid Tumours (RECIST) will be applied in order to assess change in radiological tumour size (%) from baseline to pre-surgery imaging. RECIST criteria classify response into four ordinal outcome categories: complete response, partial response, stable disease and progressive disease (see page 18)³¹. An ordinal regression model, adjusting for biological tumour type (stratification factor in the randomization), will be used to analyse differences between the treatment arms. If the proportional odds assumption of the model is violated, a nominal regression model or a generalized logistic model will be used instead if appropriate. Tumour size at histopathological assessment of the surgical specimen may be included in comparative analyses. Mean difference in reduction of tumour size between treatment arms will be analysed with an ANOVA, including biological subtype as a factor in the model.

3. Survival outcomes

All-cause, breast cancer-specific and recurrence-free survival will be analysed at 2, 5 and 10 years. Contralateral breast cancer is not regarded an event. Difference in time-to-event

outcomes between treatment arms will be compared. The mortality outcomes are defined as time from date of randomisation to death (from any cause or breast cancer as underlying cause, respectively) or censoring at end of follow-up. For recurrence-free survival, the outcome is measured as time from date of randomisation to breast cancer relapse or censoring at end of follow-up. Survival estimates after 2, 5 and 10 years of follow-up will be compared using Kaplan-Meier estimates. Furthermore, a Cox regression model, adjusting for biological subtype will also be used.

4. Health-related quality of life

All health-related quality of life outcomes are measured as scores that range from 0 to 100, hence the outcomes are continuous. Both the global QoL score as well as the 17 subscales (8 scales reflecting symptoms and 9 reflecting function) will be assessed at four time points: baseline, pre-surgery, 1 and 2 years after surgery. To evaluate QoL scores at each time point both within and between the treatment groups, a mixed model for repeated measures (MMRM) will be used. Treatment, visit, treatment visit interaction and stratification factor biological tumour type will be included in the model as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be evaluated, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry. Furthermore, differences in change from baseline between the treatment arms will be assessed at each time point by constructing relevant contrasts of the estimated regression coefficients.

5. Self-reported physical activity

Physical activity is reported using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) as total minutes per week of training in three intensity levels (light, moderate and intensive) and for weight training. Hence, the outcome is continuous. A mixed model for repeated measures (MMRM) will be used to assess physical activity at four different time points: baseline, pre-surgery, 1 and 2 years after surgery). The model will include treatment, visit, treatment-visit interaction and the stratification factor biological tumour type as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be evaluated, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry. Physical exercise will be assessed both within and between the treatment groups. Furthermore, differences in change from baseline between the treatment arms will be evaluated at each time point by constructing relevant contrasts of the estimated regression coefficients.

An additional analysis, using a dichotomous outcome that classifies patients as *active* and *insufficiently active* based on a score generated from GSLTPAQ, will be performed. Here, a generalized linear mixed model (GLMM) for repeated measures with a logit link function will be implemented. Activity will be assessed at baseline, pre-surgery and at 1- and 2-year follow-up, both within and between treatment arms. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be evaluated, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry.

6. Toxicity-related outcomes

The following toxicity-related outcomes will be assessed: a, chemotherapy completion rates, b, number of unplanned hospital admissions, c, cognitive function (measured at baseline and one year after surgery), d, cardiotoxicity and e, sick leave.

- a. Chemotherapy completion rates, i.e. the proportion of participants receiving the planned number of treatments including potential adjuvant chemotherapy, is a dichotomous outcome (yes/no). Both neoadjuvant and adjuvant treatment will be assessed separately (regarded as two independent measurements) in multivariable logistic regression models, adjusting for biological tumour type (stratification factor in the randomization). The treatment effect will be assessed in terms of a resulting odds ratio and a complementary Wald test.
- b. For the count outcome number of unplanned hospital admissions, we will use a Poisson regression model, adjusting biological tumour type. If overdispersion is present, a negative binomial regression will be considered instead. Results from the final model (Poisson or negative binomial, whichever fits the data best) will be presented as incidence ratios (IR) together with confidence intervals and a Wald test of the treatment effect.
- c. Objective cognitive dysfunction is measured by an online neuropsychological test (Amsterdam Cognition Scan) at baseline and 1-year follow-up. The total Amsterdam Cognition Scan (ACS) score, calculated as the mean of the (reversed) z-scores of all main online neuropsychological outcome measures, will be of primary interest. Furthermore, separate z-scores of the cognitive tests will also be assessed. Hence, the measured cognitive dysfunction outcomes, measured at baseline and at 1-year follow-up, are continuous variables. A mixed model for repeated measures (MMRM) will be used to assess change from baseline of ACS scores, which is the primary interest. The model will include treatment, visit and the stratification factor biological tumour type as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be evaluated, in order, until convergence is reached: toeplitz

with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry. ACS scores will be assessed both within and between the treatment groups.

- d. Cardiovascular toxicity is a dichotomous outcome (yes/no) that will be evaluated only in the subgroup of patients with HER2-positive tumours who are treated with anti-HER2 therapies (approximately 30% of the study population). A multivariable logistic regression model, adjusting for biological tumour type will be used to assess differences between the treatment arms.
- e. Sick leave is a patient-reported singular measurement at pre-surgery and at 1- and 2-year follow-up (% sick leave). Mean sick leave proportions will be compared between the treatment arms at each time point using a mixed model for repeated measures (MMRM). Treatment, visit, treatment visit interaction and the stratification factor biological tumour type will be included in the model as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be evaluated, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry. Additionally, since the outcome is most likely not normally distributed, a non-parametric Kruskal-Walllis test will be performed at each time as a sensitivity analysis.

7. Device-measured physical activity level

Several continuous outcome measures from the Fitbit activity tracker will be assessed: 1) METs (metabolic equivalents) in low, medium and high intensity activities, respectively, 2) step counts per day and 3) daily active minutes. The main interest is to see if there is a difference between the treatment arms regarding change of physical activity from baseline to pre-surgery (i.e. after intervention and chemotherapy), but also at 1-year follow-up. A mixed model for repeated measures (MMRM) with treatment, visit and the stratification factor biological subtype as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be tried, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry. Additionally, heart rates at equivalent exertion levels (assessed on the Borg scale) during physical activity will be explored.

8. Muscle strength

The muscle strength is measured on a continuous score on each arm and leg. The main interest is to see if there is a change in strength after intervention, i.e. change from baseline to pre-surgery. A mixed model for repeated measures (MMRM) with treatment, visit and the stratification factor biological tumour type as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit

of the chosen structure fails to converge, the following covariance structures will be tried, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry.

9. Cardiorespiratory fitness

The Åstrand submaximal cycle test renders a continuous outcome. The main interest is to see if there is a change in cardiorespiratory fitness after intervention, i.e. change from baseline to pre-surgery. A mixed model for repeated measures (MMRM) with treatment, visit and the stratification factor biological tumour type as fixed effects, and patient as a random effect. An unstructured covariance matrix will be used to model the within-subject error. If the fit of the chosen structure fails to converge, the following covariance structures will be tried, in order, until convergence is reached: toeplitz with heterogeneity, autoregressive with heterogeneity, toeplitz, autoregressive and compound symmetry.

REPORTING

For the secondary outcomes, the differences between the treatment arms will be reported as an effect measure (e.g. odds ratio or mean difference) together with a complementary confidence interval and a two-sided statistical test of the effect parameter. A Bonferroni corrected significance level will be used.

HANDLING MISSING VALUES AND DEATHS

Experience from previous studies have shown that this group of patients are in general highly motivated to fully participate in trials, including answering questionnaires, undergo physical exams and other assessments. Hence, it is anticipated that the dropout rate and the number of missing values will be low in both treatment arms and that this will be a minor problem in this study. Furthermore, the number of deaths during this relatively short follow-up period is also expected to be low. Nevertheless, sensitivity analysis will be performed where missing values will be assumed to be missing at random, MAR. This assumption will be already accommodated in the mixed models where repeated measurement outcomes will be analysed. For the remaining outcomes multiple imputations, assuming MAR will be performed.

A data monitoring committee consisting of three independent experts will perform a safety analysis with the purpose to assess the recruitment to the trial and the rate of adverse events, and to make sure that patients in the intervention group do not appear to fare significantly worse than patients in the standard of care group. The committee may recommend terminating the study if a significant benefit in favour of one group is shown, such that the HR for intervention versus standard of care significantly (p=0.001) exceeds 1, if the recruitment is so low that that the necessary number of events is unlikely to be reached or if

there are serious concerns about unexpected AEs in the intervention group. If the committee determines that it is safe to proceed with the study, the results of the analysis will remain unknown to everyone except the committee members.

ETHICAL CONSIDERATIONS

The original version of this trial protocol has been approved by the Ethics Committee of the Karolinska Institutet, Stockholm (Dnr 2022-02084-01).

Physical exercise during chemotherapy is deemed feasible and safe¹⁹. Potential adverse events, such as cardiovascular and musculoskeletal symptoms, will be recorded throughout the NACT period and participants who experience serious adverse events will discontinue trial participation. Adverse events that are ascribed NACT but not the trial intervention will be handled in accordance to clinical routine by the responsible oncologists. There is no evidence that the intervention may lead to inferior results concerning the primary or secondary endpoints. Instead, there are data from studies in the adjuvant setting showing a preserved health-related quality of life, lower rate of self-reported symptoms related to treatment, and higher chemotherapy completion rates. In addition, this trial offers patient empowerment that is generally experienced as a positive aspect of treatment. Therefore, participation in this trial is judged ethically highly feasible.

WITHDRAWAL

Patients who wish to withdraw from the trial may do so at any time, without providing a reason. Data already included in previous eCRFs will be included in the analysis and linkage to national registers will be performed if the participant does not explicitly wish to have his/her data excluded from analysis. Ceasing participation will be recorded in the eCRF.

PUBLICATION POLICY

Before the collaborative publication of the main outcome from the entire cohort, no other publication regarding the primary outcome on the whole or parts of the cohort can be attempted. Publications of secondary endpoints or the trial protocol may be undertaken prior to the main publication. Each principal investigator is a co-author in any publication reporting on pre-planned analyses from the Neo-ACT trial, that is, any report on primary or secondary outcomes, protocol, safety reports or translational substudies. Any further analysis using the full or parts of the clinical dataset from the Neo-ACT trial must first get the permission from the principal investigators. The principal investigators must in such case be permitted to take a more active part and thus fulfil the ICMJE criteria for authorship. Any

investigators not fulfilling ICMJE criteria for authorship must be individually named in Acknowledgements.

TIME PLAN

Based on our experience in the OptiTrain trial, the rate of informed consent in patients up to the age of 70 years is about 50%. Participation rates may potentially rise in this trial since awareness of the benefits of physical exercise in the context of cancer has increased and since Neo-ACT for the first time offers a real-time measurement of the anti-tumoral effects of physical exercise which may offer the participants prognostic gains. However, competing oncological trials investigating pCR rates may negatively affect participation rates: Currently, in spring of 2022, the Swedish PREDIX Luminal B trial is closed, while the ongoing Nordic Trip trial includes patients with T2-3 or node-positive triple-negative breast cancer. Further potential Swedish trials, such as the ARIADNE trial in HER2+ patients, may be initiated in the near future.

In 2020, the proposed trial sites (at the time of writing 10 Swedish and 1-7 Finnish sites) registered over 900 newly diagnosed BC patients receiving NACT. The proportion of NACT has been increasing over the last years, and a decline is not anticipated. With an estimated participation rate of one third, more than 300 patients may be enrolled per year. Accrual rates will be monitored each month and further sites may be opened if accrual drops below estimated rates. The Neo-ACT trial is planned to open for recruitment in October 2022, and it is estimated that inclusion may be completed in December 2025. An independent interim safety analysis is performed after recruitment of 200 patients or after two years, whatever occurs first. The primary endpoint is analysed once all participants have had surgery. Follow-up will be two years per individual.

TRANSLATIONAL RESEARCH

The following translational projects are proposed. This list does not claim to be complete, and further translational projects may be added to the trial at any time point.

FAECES MICROBIOME

A growing research interest has arisen in the association between the composition of the intestinal microbiome and development and treatment-related outcomes of cancer. Especially the association between response to immune checkpoint inhibitors (ICI) and the intestinal microbiome is of great relevance, where pre-clinical and clinical studies have shown that presence of certain forms of microbiome components as well as recent and

current use of antibiotics are associated with a lack of ICI treatment effect^{37,38}. Intervention studies using faeces modification with the aim to change the intestinal microbiome and thereby potentially improve the response to ICI treatment are ongoing. First results are promising³⁹.

Physical exercise increases the number of beneficial microbial species, leads to an enrichment of the microflora diversity, and an improved development of commensal bacteria⁴⁰. Proposed mechanisms include the release of neuroendocrine and immune-modulatory factors, which in turn may lower inflammatory and oxidative stress, and thereby beneficially affect metabolic disorders⁴¹.

The interplay between physical exercise, cancer and the intestinal microbiome is insufficiently explored. In a study in 15 patients who underwent resection for early-stage lung cancer, the gut-lung axis was investigated through paired faeces samples pre- and post-surgery. Changes in microbial community functional profiles were observed between both time points, as well as an association between functional capacity (VO2) and an increase in certain microbiotic species⁴². A randomised controlled trial was recently initiated exploring the impact of a three-month exercise programme for men with high-risk prostate cancer on androgen deprivation therapy on the intestinal microbiome and gut health. Gut health and gut function assessed via faecal samples is the primary endpoint whereas secondary endpoints include self-reported quality of life⁴³.

In Neo-ACT, clinical data on antibiotic and proton-pump inhibitor (self-reported) use up to six months pre-baseline will be registered. Faeces will be collected at baseline and before surgery. Changes in microbiome will be compared between the randomization groups and over time.

INTRATUMORAL AND CIRCULATING NATURAL KILLER (NK) CELLS

Transplantation studies show that NK cells are involved in tumor rejection and protection from relapse, supporting the therapeutic potential of NK cells in tumor eradication ^{44,45}. Despite these encouraging findings, NK cell therapies are limited by the lack of antigen specificity. Also, similar to T cells, resistance to NK cell-mediated killing may develop due to the recruitment and differentiation of immune suppressive cells, including regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC), and overexpression of immune inhibitory checkpoint proteins in the tumor microenvironment (TME). The adaptive NK (aNK) cell subset, defined by the expression of the maturation marker CD57, the activation receptor NKG2C, and the downregulation of several signaling molecules including PLZF, Syk, and FC ϵ R1 γ , is able to resist the TME suppression by MDSC and Treg involves low expression of the checkpoint molecules T cell immunoglobulin and ITIM domain (TIGIT), programed death receptor (PD-1), NKG2A, and the IL-1R8 ^{46,47}.

Samples from tumor and blood will be collected at two time points; at baseline prior to start of chemotherapy as well as at surgery. For this purpose, one fresh core biopsy and two tubes of heparin blood are utilized.

The aim is to identify biomarkers/predictive markers associated with aNK cells in patients with breast cancer undergoing NACT with and without physical exercise. Examinations will enable identification of new biomarkers that determine the endpoint of NACT and long-term clinical responses. The specific aims are to characterize aNK cells in breast cancer and exploit whether NACT and physical exercise harness aNK cell memory and to investigate aNK cell interaction with other cells in the TME comparing the two trial groups.

TUMOUR GENE PROFILING

RNA and DNA will be extracted from RNAlater and/or FFPE-preserved biopsies from the primary tumour (preoperative core biopsies as well as surgically resected tumours after NACT), axillary metastases and distant/local recurrences for further analysis. Gene expression profiling will be performed to identify intrinsic subtypes, molecular signalling pathways and additional programs or genes associated with pathological response and with additional biomarkers and physical activity. DNA sequencing (exome, whole genome or targeted panels) will investigate any genomic variants.

TUMOUR MICROENVIRONMENT

Baseline presence and composition of tumour-infiltrating lymphocytes (TILs) are prognostic in triple-negative and HER2-positive breast cancers treated with neoadjuvant systemic therapy, and predictive for pCR^{48,49}. TILs will be assessed by pathologists in the untreated primary tumour biopsy and the surgical specimen according to international guidelines (<u>https://www.tilsinbreastcancer.org/</u>). Even beyond TILs, the tumor microenvironment plays a crucial role in the response to neoadjuvant chemotherapy. Our hypothesis is that the study intervention (physical exercise) can improve pCR rates in tumors that are immunologically cold at baseline.

A study-specific tumor biopsy will be obtained from all study participants before start of neoadjuvant therapy (baseline biopsy) and will be formalin-fixed and paraffin embedded (FFPE). Similarly, tumor material will be obtained from the surgical specimen. Whole sections will be used for H&E staining and subsequently scanning for digital pathology and deep-learning image analyses. Tumor infiltrating lymphocytes (TILs) will be correlated with

clinical characteristics and outcomes. Tissue microarrays (TMAs) will be fabricated and will be used for multiplex immunofluorescence assays for characterization of tumor cells, immune and other cell types in the tumor stroma both at baseline and at surgery. For this purpose. the 7-color IHC method (Opal 7 Solid Tumor Immunology Kit, PerkinElmer) using a panel of lymphocytic and macrophage markers and an additional panel of fibroblast, blood vessel and mesenchymal cell markers will be utilized. Multispectral fluorescent scanning (Vectra 3 Quantitative Pathology Systems) and image analysis with compatible software will be used for the visualization and quantitation of the multiple markers in a spatial tissue context.

CIRCULATING TUMOUR CELLS AND TUMOUR DNA

DNA analysis will be performed in blood plasma specimens from the patients (liquid biopsy). Genomic variants will be compared in different localisations and sample types to investigate clonality and tumour evolution.

THE EFFECTS OF HUMAN ADIPOCYTES ON BREAST CANCER PROGRESSION AND METASTASIS

The worldwide prevalence of obesity nearly tripled during the past decades. Overall, in 2016 about 13% of the world's adult population were obese. Obesity rates in Sweden have also increased, with almost 20% of Swedes between 45-84 years old being obese. The global obesity rate in women is projected to reach 21% by 2025 and this is particularly alarming considering that 55% of all female cancers have an obesity-associated mechanism⁵⁰. Obesity is defined as an abnormal excessive fat accumulation that causes a health risk. Body Mass Index (BMI) is a useful index of weight-for-height that is commonly used to classify this pathology. Obesity increases the risk for many types of cancer and is associated with poor outcomes. Despite a strong association with obesity, most current cancer treatments do not take into consideration the ongoing obesity epidemic. Whilst preventative measures, such as promoting weight loss should be conducted, often once cancer has been detected there may not be time to lose weight before treatment. As such, there is a need to develop specific drug targets that could be leveraged to address the obesity component of the disease.

In breast cancer obesity is only associated with an increased incidence of post-menopausal breast cancer, whilst obesity is a risk factor for progression in all breast cancer subtypes⁵¹. An important and negative predictor of cancer survival is metastasis. The mechanism underlying the metastatic spread of cancer including Epithelial-Mesenchymal-Transition (EMT), cell migration, progression, and dissemination remains unclear. The EMT is a critical tumour cell plasticity and dedifferentiation program, by which epithelial cells acquire promigratory and invasive mesenchymal properties. The effects of non-cancer associated

adipocytes on promoting EMT and cancer progression in lean and obese individuals remain largely unknown⁵².

In the Neo-ACT trial, we will acquire fresh fat tissues from the operated breast regardless of the NACT response of the individual patient. We will address the following questions as specific study aims:

1. Determine the potential effect of NACT on breast tissue fat cells senescence.

2. Determine whether adipocyte senescence level correlates with exercise and leads to different secretion patterns of various soluble factors and therefore enhances the attraction/infiltration of immune cells.

3. Determine whether factors secreted by adipocytes in resting versus exercising individuals are correlated with treatment response.

4. Determine whether patients from different BMI groups (both before and after exercises) have distinct response patterns and if adipose tissues play a role in it.

5. Identify possible biomarkers for breast cancer-associated adipocytes and their possible implications in breast cancer treatment regimen design (eg. CDK4/6 inhibitors).

The methods include basic cell and molecular experiment procedures including but not limited to culturing of patient adipocytes, staining, as well as RNAseq analysis. The results can be analysed together with the RNAseq results of biopsy/residual tumours, as well as the flow cytometry data to find connections with immune infiltration patterns. Blood testing results will be vital for subgroup patient populations and correlation analysis.

DEEP PROTEOMICS OF INFLAMMATORY REGULATORS IN CANCER

Inflammation and the escape from immune system are unavoidable events in cancer growth and progression, both in solid tumors and in hematological malignancies. Inflammatory cytokines and their receptors have an essential role as the regulator of tumor immunity and inflammation. They form a complex regulatory network where single factors play only minor roles in the broader context of inflammation-related carcinogenesis.

In most early-stage cancers, including breast cancer and colorectal cancer, perioperative inflammation has been studied traditionally by assessing a neutrophil-to-lymphocyte-ratio, which has shown significant potential as a prognostic marker. No studies combining hundreds of inflammatory biomarkers to prospective collected, highly data-intense material exist so far in breast cancer literature. This inflammatory index, consisting of hundreds of inflammatory-related regulators could have stronger predictive power than neutrophil-to-lymphocyte-ratio assessments. By studying a vast network of inflammatory cytokines, significant advantages in understanding the relationship between inflammation and cancer progression could be achieved. There are preliminary data from various cancer types that

perioperative treatment with non-steroidal anti-inflammatory drugs could reduce invasion and increase survival rates in the patients with highest inflammatory status^{53,54}.

Through measurement of large cytokine regulatory networks from the blood stream, lung cancer and breast cancer patients have been recently reliably classified to different prognostic classes⁵⁵⁻⁵⁷. However, these studies used retrospective data and the number of patients was limited. Although the published results are promising regarding their prognostic value, it has not been possible to evaluate the connection between cytokine networks and e.g. treatment toxicity in the published studies.

The unique aspect of this substudy to the Neo-ACT trial is to combine the network of hundreds of cancer-relevant inflammatory and anti-inflammatory cytokines and their receptors with a serially collected, data from the clinical trial, from patients receiving the modern oncological treatments.

Aim: Do inflammation-related and immunity-related cytokines, their receptors or other inflammation or immune response-regulating cytokines have an association with (a) the efficacy of the exercise intervention, (b) breast cancer subtype or stage, (c) the prognosis of the patients, (d) the structure of gut microbiome, or (e) the toxicity of the neoadjuvant chemotherapy?

Methods: The serum expression of inflammatory cytokines, their receptors and other cytokines will be studied using a high-throughput, multiplex Olink Proximity Extension Assay immunoassay (Olink, Uppsala, Sweden) enabling a simultaneous high-throughput analysis of 384 inflammatory biomarkers. This method allows us to study an exceptional specificity of multiple biomarkers and especially their networks. Currently, Olink offers the only commercially available Proximity Extension Assay in the market. Again, it is impossible to measure the expression of hundreds of proteins with conventional multiplexing. More specific details of the assay can be found at https://www.olink.com/products/olink-explore-384-inflammation/. Assessments will be done both from the baseline and pre-surgical blood samples, which allows us to evaluate not only the single values of inflammatory networks, but also the dynamic changes of the studied proteins to the outcomes defined above.

REFERENCES

- 1. RCC. *Nationellt vårdprogram [Swedish National Guidelines]*. Regionala cancercentrum i samverkan;2020.
- 2. Burstein HJ, Curigliano G, Thurlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Ann Oncol.* 2021;32(10):1216-1235.
- 3. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet.* 2014;384(9938):164-172.
- 4. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2012;13(1):25-32.
- 5. Early Breast Cancer Trialists' Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *Lancet Oncol.* 2018;19(1):27-39.
- 6. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. *N Engl J Med.* 2020;382(9):810-821.
- 7. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. *N Engl J Med.* 2017;376(22):2147-2159.
- 8. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. *N Engl J Med.* 2019;380(7):617-628.
- 9. Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. *Methods Mol Biol.* 2009;472:191-215.
- 10. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science*. 2003;302(5645):643-646.
- 11. Betof AS, Dewhirst MW, Jones LW. Effects and potential mechanisms of exercise training on cancer progression: a translational perspective. *Brain Behav Immun.* 2013;30 Suppl:S75-87.
- 12. Schadler KL, Thomas NJ, Galie PA, et al. Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. *Oncotarget.* 2016;7(40):65429-65440.
- 13. McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. *J Natl Cancer Inst.* 2014;106(4):dju036.
- 14. Rogers CJ, Zaharoff DA, Hance KW, et al. Exercise enhances vaccine-induced antigen-specific T cell responses. *Vaccine*. 2008;26(42):5407-5415.
- 15. Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. *Nat Rev Clin Oncol.* 2016;13(4):228-241.
- 16. Gustafson MP, DiCostanzo AC, Wheatley CM, et al. A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood. *J Immunother Cancer.* 2017;5:30.
- 17. Hojman P, Gehl J, Christensen JF, Pedersen BK. Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. *Cell Metab.* 2018;27(1):10-21.
- 18. Pedersen L, Idorn M, Olofsson GH, et al. Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. *Cell Metab.* 2016;23(3):554-562.

- 19. Zylstra J, Whyte GP, Beckmann K, et al. Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. *Br J Sports Med.* 2022;56(7):402-409.
- 20. Loughney L, West MA, Kemp GJ, Grocott MP, Jack S. Exercise intervention in people with cancer undergoing neoadjuvant cancer treatment and surgery: A systematic review. *Eur J Surg Oncol.* 2016;42(1):28-38.
- 21. Sturgeon KM, Smith AM, Federici EH, et al. Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients. *BMC Sports Sci Med Rehabil.* 2022;14(1):31.
- 22. Cormie P, Zopf EM, Zhang X, Schmitz KH. The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. *Epidemiol Rev.* 2017;39(1):71-92.
- 23. Courneya KS, Segal RJ, McKenzie DC, et al. Effects of exercise during adjuvant chemotherapy on breast cancer outcomes. *Med Sci Sports Exerc.* 2014;46(9):1744-1751.
- 24. Hayes SC, Steele ML, Spence RR, et al. Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials. *Breast Cancer Res Treat.* 2018;167(2):505-514.
- 25. Mijwel S, Backman M, Bolam KA, et al. Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. *Breast Cancer Res Treat.* 2018;169(1):93-103.
- 26. Mijwel S, Cardinale DA, Norrbom J, et al. Exercise training during chemotherapy preserves skeletal muscle fiber area, capillarization, and mitochondrial content in patients with breast cancer. *FASEB J.* 2018;32(10):5495-5505.
- 27. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. *BMC Med.* 2015;13:195.
- 28. van Waart H, Stuiver MM, van Harten WH, et al. Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. *J Clin Oncol.* 2015;33(17):1918-1927.
- 29. Xu L, Li F, Zhou C, Li J, Hong C, Tong Q. The effect of mobile applications for improving adherence in cardiac rehabilitation: a systematic review and meta-analysis. *BMC Cardiovasc Disord*. 2019;19(1):166.
- 30. Groen WG, van Harten WH, Vallance JK. Systematic review and meta-analysis of distance-based physical activity interventions for cancer survivors (2013-2018): We still haven't found what we're looking for. *Cancer Treat Rev.* 2018;69:188-203.
- 31. Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1 Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. *Eur J Cancer.* 2016;62:138-145.
- 32. Tolaney SM, Garrett-Mayer E, White J, et al. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. *J Clin Oncol.* 2021;39(24):2720-2731.
- 33. Feenstra HEM, Murre JMJ, Vermeulen IE, Kieffer JM, Schagen SB. Reliability and validity of a selfadministered tool for online neuropsychological testing: The Amsterdam Cognition Scan. J Clin Exp Neuropsychol. 2018;40(3):253-273.
- 34. SERVICES UDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. In:2017.
- 35. EMA. Statistical Principles for Clinical Trials. <u>https://www.ema.europa.eu/en/ich-e9-statistical-principles-clinical-trials#current-version-section</u>. Published 1998. Accessed.
- 36. EMA. Guideline on adjustment for baseline covariates in clinical trials. <u>https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-adjustment-baseline-covariates-clinical-trials_en.pdf</u>. Published 2015. Accessed.

- 37. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science*. 2018;359(6371):97-103.
- 38. Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. *Cell*. 2016;165(2):276-287.
- 39. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*. 2018;359(6371):91-97.
- 40. Monda V, Villano I, Messina A, et al. Exercise Modifies the Gut Microbiota with Positive Health Effects. *Oxid Med Cell Longev.* 2017;2017:3831972.
- 41. Sohail MU, Yassine HM, Sohail A, Thani AAA. Impact of Physical Exercise on Gut Microbiome, Inflammation, and the Pathobiology of Metabolic Disorders. *Rev Diabet Stud.* 2019;15:35-48.
- 42. Marfil-Sanchez A, Seelbinder B, Ni Y, et al. Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients. *PLoS One.* 2021;16(11):e0259898.
- 43. Newton RU, Christophersen CT, Fairman CM, et al. Does exercise impact gut microbiota composition in men receiving androgen deprivation therapy for prostate cancer? A single-blinded, two-armed, randomised controlled trial. *BMJ Open.* 2019;9(4):e024872.
- 44. Miller JS, Cooley S, Parham P, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. *Blood*. 2007;109(11):5058-5061.
- 45. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science*. 2002;295(5562):2097-2100.
- 46. Luu TT, Ganesan S, Wagner AK, et al. Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+dendritic cells. *Scientific Reports.* 2016;6.
- 47. Sarhan D, Hippen KL, Lemire A, et al. Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. *Cancer Immunol Res.* 2018;6(7):766-775.
- 48. Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. *PLoS One*. 2014;9(12):e115103.
- 49. Hong J, Rui W, Fei X, Chen X, Shen K. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. *Cancer Med.* 2021;10(22):7921-7933.
- 50. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. *Trends Cancer*. 2018;4(5):374-384.
- 51. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. *Nat Rev Cancer*. 2015;15(8):484-498.
- 52. Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. *Cancer Res.* 2011;71(7):2455-2465.
- 53. Ricon I, Hanalis-Miller T, Haldar R, Jacoby R, Ben-Eliyahu S. Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of beta-adrenergic and cyclooxygenase 2 signaling. *Cancer.* 2019;125(1):45-56.
- 54. Huang Z, Wang X, Zou Q, et al. High platelet-to-lymphocyte ratio predicts improved survival outcome for perioperative NSAID use in patients with rectal cancer. *Int J Colorectal Dis.* 2020;35(4):695-704.
- 55. Barrera L, Montes-Servin E, Barrera A, et al. Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis. *Ann Oncol.* 2015;26(2):428-435.

Physical exercise during neoadjuvant chemotherapy for breast cancer: Neo-ACT

- 56. Li B, Geng R, Wu Q, et al. Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer. *Front Oncol.* 2020;10:333.
- 57. Do HTT, Lee CH, Cho J. Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers. *Cancers (Basel)*. 2020;12(2).

Signering av etikprövningsansökan

Ansökan om ändring

Forskningshuvudman: Karolinska Institutet

Projekttitel: Fysisk träning under preoperativ cellgiftsbehandling för bröstcancer för att öka andelen patienter som får komplett tumörrespons: den randomiserade Neo-ACT studien

I och med att ansökan undertecknas intygar du som är ansvarig forskare följande:

- Att den information som lämnas i ansökan om etikprövning och samtliga medföljande bilagor är riktig och fullständig.
- Att verksamhetsansvariga i samtliga medverkande verksamheter är informerade om forskningsprojektets innehåll och utförande och att de har samtyckt till att delta i studien.
- Att du säkerställt att det i samtliga medverkande verksamheter finns resurser som garanterar forskningspersonernas säkerhet och integritet vid genomförandet av den forskning som beskrivs i ansökan.
- Att du tagit del av Etikprövningsmyndighetens information om hantering av personuppgifter på myndighetens webbplats.



Ansvarig forskare har signerat.

Signerat av JANA DE BONIFACE 2023-02-10 12:01:00

Signering av etikprövningsansökan

Ansökan om ändring

Forskningshuvudman: Karolinska Institutet

Projekttitel: Fysisk träning under preoperativ cellgiftsbehandling för bröstcancer för att öka andelen patienter som får komplett tumörrespons: den randomiserade Neo-ACT studien

I och med att ansökan undertecknas intygar du som är behörig företrädare följande:

- Att den information som lämnas i ansökan om etikprövning och samtliga medföljande bilagor är riktig och fullständig.
- Att verksamhetsansvariga i samtliga medverkande verksamheter är informerade om forskningsprojektets innehåll och utförande och att de har samtyckt till att delta i studien.
- Att du säkerställt att det i samtliga medverkande verksamheter finns resurser som garanterar forskningspersonernas säkerhet och integritet vid genomförandet av den forskning som beskrivs i ansökan.
- Att ansvarig forskare ges rätt att företräda huvudmannen i alla framtida kontakter med Etikprövningsmyndigheten som rör detta forskningsprojekt samt ansöka om ändringar i forskningsprojektet.
- Att du tagit del av Etikprövningsmyndighetens information om hantering av personuppgifter på myndighetens webbplats.



Behörig företrädare har signerat.

Signerat av ANDERS FRANCO CERECEDA 2023-02-10 12:16:25

Q

Avgiftsavisering

Etikprövningsmyndigheten har tagit emot din ansökan med titel Fysisk träning under preoperativ cellgiftsbehandling för bröstcancer för att öka andelen patienter som får komplett tumörrespons: den randomiserade Neo-ACT studien om ändring. Ansökan har diarienummer 2023-01017-02 vilket alltid ska anges i framtida kontakter i ärendet.

Avgiften för ansökan om ändring, som är 2000 kronor, ska omgående betalas in enligt nedan:

- Inbetalning sker till bankgironummer 406-1107
- Vid inbetalning ska OCR-nummer 2023010170231 anges som referens.
- Inga andra bokstäver eller siffror får anges i raden för referens.

Först när ärendet kompletterats enligt ovan kommer vi att påbörja handläggningen.

Etikprövningsmyndigheten Telefon: 010 - 475 08 00 Webbplats: www.etikprovning.se